[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567402":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":61,"centralContacts":66,"locations":73,"responsibleParty":89,"collaborators":91,"id":95,"slug":71,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":71,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":71,"enrollmentInfo":103,"targetDuration":71,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":71,"overallStatus":75,"whyStopped":71,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (18F-DOPA)","EXPERIMENTAL","Patients receive 18F-DOPA IV and undergo PET\u002FCT over 30 minutes on day 1.",[13,14,15],"Procedure: Computed Tomography","Drug: Fluorodopa F 18","Procedure: Positron Emission Tomography",[17,33,49],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"PROCEDURE","Computed Tomography","Undergo PET\u002FCT",[9],[23,24,25,26,27,28,29,30,31,32],"CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography",{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","Fluorodopa F 18","Given IV",[9],[39,40,41,42,43,44,45,46,47,48],"(18F)FDOPA","18F-DOPA","18F-FDOPA","3-(2-Fluoro-(sup 18)F-4,5-dihydroxyphenyl)-L-alanine","6-(18F)Fluoro-L-DOPA","Fluorine F 18 Fluorodopa","Fluorine-18-fluoro-L-DOPA","Fluorodopa (18F)","FLUORODOPA F-18","L-6-(18F)Fluoro-DOPA",{"type":18,"name":50,"description":20,"armGroupLabels":51,"otherNames":52},"Positron Emission Tomography",[9],[53,54,55,56,57,58,59,60],"Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","proton magnetic resonance spectroscopic imaging","PT",[62],{"name":63,"affiliation":64,"role":65},"Derek R. Johnson, MD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[67],{"name":68,"role":69,"phone":70,"phoneExt":71,"email":72},"Clinical Trials Referral Office","CONTACT","855-776-0015",null,"mayocliniccancerstudies@mayo.edu",[74],{"facility":64,"status":75,"city":76,"state":77,"zip":78,"country":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":86},"RECRUITING","Rochester","Minnesota","55905","United States",{"type":81,"coordinates":82},"Point",[83,84],-92.4699,44.02163,{"lat":84,"lon":83},[87,88],{"name":68,"role":69,"phone":70,"phoneExt":71,"email":72},{"name":63,"role":65,"phone":71,"phoneExt":71,"email":71},{"type":90,"investigatorFullName":71,"investigatorTitle":71,"investigatorAffiliation":71,"oldNameTitle":71,"oldOrganization":71},"SPONSOR",[92],{"name":93,"class":94},"Food and Drug Administration (FDA)","FED","100567402",false,"NCT06667726","An Investigational Scan (18F-DOPA PET\u002FCT) for Improving the Clinical Management of Brain Tumors","A Centralized Protocol Evaluating the Safety and Clinical Impact of Amino Acid Pet for Brain Tumors","Inclusion Criteria:\n\n* Age 18 and older\n* Diagnosis of a brain tumor\n* Indication for amino acid PET imaging, including presurgical evaluation, radiation planning, MR imaging indeterminate for progression versus treatment effect, or clinical need for enhanced monitoring\n* Ability to give appropriate consent or have an appropriate representative available to do so\n\nExclusion Criteria:\n\n* Patient is unable to undergo PET imaging\n* Persons who are pregnant or nursing","ALL","18 Years",{"count":104,"type":105},47,"ESTIMATED","INTERVENTIONAL",[108],"PHASE2","This phase II trial studies how well the addition of 18F-DOPA (amino acid) positron emission tomography (PET)\u002Fcomputed tomography (CT) to standard of care (SOC) imaging can improve the clinical management of patients with brain tumors in over 50% of cases. PET is an imaging test that helps to measure the information about functions of tissues and organs within the body. A PET scan uses a radioactive drug (radiotracer) to show this activity. CT scan uses X-rays to create images of the bones and internal organs within the body. Combining a PET scan with a CT scan can help make the images easier to interpret. PET\u002FCT scans are hybrid scanners that combine both of the two modalities into a single scan. This allows images of both anatomy (CT) and function (PET) to be taken during the same scan. The 18F-DOPA PET\u002FCT scan is done with a very small amount of a radioactive tracer called FDOPA. The PET\u002FCT scan is then used to detect the location of tumors. Using the 18FDOPA-PET\u002FCT scan in addition to the SOC scan may improve the clinical management of patients with brain tumors.",[111],"Malignant Brain Neoplasm","2026-04-23",{"date":114,"type":115},"2026-04-28","ACTUAL",{"date":117,"type":115},"2026-03-24",{"date":119,"type":105},"2028-05-31",{"name":5,"class":6},1]